Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul N Schacknow

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Annals of Emergency Medicine|September 19, 2023
Sudden Cardiac Death at Home: Potential Lives Saved With Fully Automated External DefibrillatorsLawrence J Gessman, Paul N Schacknow, Ralph G Brindis
American Journal of Ophthalmology|February 5, 2003
Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertensionDouglas G Day, Paul N Schacknow, Martin Wand, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|January 15, 2005
A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertensionDouglas G Day, Paul N Schacknow, Elizabeth D Sharpe, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|January 13, 2006
A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucomaPaul P Lee, John G Walt, John J Doyle, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Annals of Emergency Medicine|September 19, 2023
Sudden Cardiac Death at Home: Potential Lives Saved With Fully Automated External DefibrillatorsLawrence J Gessman, Paul N Schacknow, Ralph G Brindis
American Journal of Ophthalmology|February 5, 2003
Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertensionDouglas G Day, Paul N Schacknow, Martin Wand, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|January 15, 2005
A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertensionDouglas G Day, Paul N Schacknow, Elizabeth D Sharpe, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|January 13, 2006
A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucomaPaul P Lee, John G Walt, John J Doyle, et al.
Pageof 1